The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.9M data for 1.2M Compounds and 9.3K Targets. Of those, 1,352K data for 627K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

10 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Identification and development of biphenyl substituted iminosugars as improved dual glucosylceramide synthase/neutral glucosylceramidase inhibitors.EBI
Leiden University
The many faces of the adamantyl group in drug design.EBI
University of Sydney
Assessment of partially deoxygenated deoxynojirimycin derivatives as glucosylceramide synthase inhibitors.EBI
TBA
Identification of Potent and Selective Glucosylceramide Synthase Inhibitors from a Library of N-Alkylated IminosugarsEBI
TBA
Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation.EBI
Leiden University
Nanomolar affinity, iminosugar-based chemical probes for specific labeling of lysosomal glucocerebrosidase.EBI
Utrecht University
Synthesis and evaluation of D-gluco-pyranocyclopropyl amines as potential glucosidase inhibitors.EBI
Leiden University
Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis.EBI
University of Oxford
Exploring the effect of chirality on the therapeutic potential of N-alkyl-deoxyiminosugars: anti-inflammatory response to Pseudomonas aeruginosa infections for application in CF lung disease.EBI
University of Napoli Federico Ii
4-epi-Isofagomine derivatives as pharmacological chaperones for the treatment of lysosomal diseases linked to ?-galactosidase mutations: Improved synthesis and biological investigations.EBI
Universit£